Patents by Inventor Shuli MA

Shuli MA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11357826
    Abstract: The present disclosure provides proteinaceous complexes, pharmaceutical compositions, medicaments and/or kits comprising the proteinaceous complexes, methods for producing the proteinaceous complexes, and uses thereof.
    Type: Grant
    Filed: August 21, 2019
    Date of Patent: June 14, 2022
    Assignee: DINGFU BIOTARGET CO., LTD.
    Inventors: Ting Xu, Yan Luan, Jianjian Peng, Shuli Ma, Meng Zhao, Xiaoxiao Wang, Hui Ma, Shilong Fu, Xiaolong Pan, Shanshan Ning
  • Publication number: 20210380708
    Abstract: An antibody may be capable of specifically binding CD137 or an antigen binding fragment thereof, wherein the light chain variable region and the heavy chain variable region have one or more mutations. The antibody or antigen binding fragment thereof may be used in preparing a drug. The antibody or an antigen binding fragment thereof may specifically bind CD137, and may include a light chain variable region VL and a heavy chain variable region VH, wherein compared to a sequence as shown in SEQ ID NO: 103, the VL comprises one or more VL amino acid mutations, and the VL amino acid mutation occurs at one or more positions: V3, A10, K44, D71, and/or V77.
    Type: Application
    Filed: September 12, 2019
    Publication date: December 9, 2021
    Applicant: DINGFU BIOTARGET CO., LTD.
    Inventors: Xin ZHANG, Jianjian PENG, Kai FU, Hui MA, Xiaolong PAN, Shilong FU, Shuli MA, Jian DING
  • Patent number: 10875926
    Abstract: Disclosed are a fully human monoclonal antibody specifically binding to a CD137 or an antigen binding portion thereof. On one hand, provided are a CDR/variable region sequence of the antibody and an encoding nucleic acid sequence thereof; on the other hand, provided is a method for treating diseases using the antibody or the antigen binding portion thereof. a fully human monoclonal antibody specifically binding to a CD137 or an antigen binding portion thereof. On one hand, provided are a CDR/variable region sequence of the antibody and an encoding nucleic acid sequence thereof; on the other hand, provided is a method for treating diseases using the antibody or the antigen binding portion thereof.
    Type: Grant
    Filed: September 22, 2015
    Date of Patent: December 29, 2020
    Assignee: Dingfu Biotarget Co., Ltd.
    Inventors: Ting Xu, Yan Luan, Xiaoxiao Wang, Jianjian Peng, Shuli Ma, Hui Ma, Xiaolong Pan, Shilong Fu, Shanshan Ning, Yeqiong Fei, Meng Zhao
  • Patent number: 10624974
    Abstract: The present application provides an anti-OX40 human antibody. In particular, a human antibody specifically binding to OX40 is obtained with yeast display screening, and the affinity of the antibody is improved with affinity maturation. The present application also provides a use of the antibody for the prevention or treatment of tumors.
    Type: Grant
    Filed: October 15, 2015
    Date of Patent: April 21, 2020
    Assignee: Dingfu Biotarget Co., Ltd.
    Inventors: Ting Xu, Yan Luan, Xiaoxiao Wang, Jianjian Peng, Shuli Ma, Hui Ma, Xiaolong Pan, Shilong Fu, Shanshan Ning, Yeqiong Fei, Meng Zhao
  • Publication number: 20200069773
    Abstract: The present disclosure provides proteinaceous complexes, pharmaceutical compositions, medicaments and/or kits comprising the proteinaceous complexes, methods for producing the proteinaceous complexes, and uses thereof.
    Type: Application
    Filed: August 21, 2019
    Publication date: March 5, 2020
    Applicant: DINGFU BIOTARGET CO., LTD.
    Inventors: Ting XU, Yan LUAN, Jianjian PENG, Shuli MA, Meng ZHAO, Xiaoxiao WANG, Hui MA, Shilong FU, Xiaolong PAN, Shanshan NING
  • Patent number: 10471124
    Abstract: The present disclosure provides proteinaceous heterodimers, pharmaceutical compositions, medicaments and/or kits comprising the proteinaceous heterodimers, methods for producing the proteinaceous heterodimers, and uses thereof.
    Type: Grant
    Filed: November 10, 2015
    Date of Patent: November 12, 2019
    Assignee: DINGFU BIOTARGET CO., LTD.
    Inventors: Ting Xu, Yan Luan, Jianjian Peng, Shuli Ma, Meng Zhao, Xiaoxiao Wang, Hui Ma, Shilong Fu, Xiaolong Pan, Shanshan Ning
  • Publication number: 20180282422
    Abstract: Disclosed are a fully human monoclonal antibody specifically binding to a CD137 or an antigen binding portion thereof. On one hand, provided are a CDR/variable region sequence of the antibody and an encoding nucleic acid sequence thereof; on the other hand, provided is a method for treating diseases using the antibody or the antigen binding portion thereof. a fully human monoclonal antibody specifically binding to a CD137 or an antigen binding portion thereof. On one hand, provided are a CDR/variable region sequence of the antibody and an encoding nucleic acid sequence thereof; on the other hand, provided is a method for treating diseases using the antibody or the antigen binding portion thereof.
    Type: Application
    Filed: September 22, 2015
    Publication date: October 4, 2018
    Inventors: Ting XU, Yan LUAN, Xiaoxiao WANG, Jianjian PENG, Shuli MA, Hui MA, Xiaolong PAN, Shilong FU, Shanshan NING, Yeqiong FEI, Meng ZHAO
  • Publication number: 20170340708
    Abstract: The present disclosure provides proteinaceous heterodimers, pharmaceutical compositions, medicaments and/or kits comprising the proteinaceous heterodimers, methods for producing the proteinaceous heterodimers, and uses thereof.
    Type: Application
    Filed: November 10, 2015
    Publication date: November 30, 2017
    Inventors: Ting XU, Yan LUAN, Jianjian PENG, Shuli MA, Meng ZHAO, Xiaoxiao WANG, Hui MA, Shilong FU, Xiolong PAN, Shanshan NING